10 recruiting, 8 completed, 6 terminated, 5 active not recruiting. 20 Phase 2, 9 Not applicable, 4 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow Radical Cystectomy: new trials by email Literature Review of Radical Cystectomy trials Research Report on Radical Cystectomy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-09-17 |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab - Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2026-09-01 | 2026-09-03 | |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC Gemcitabine, Toripalimab, Disitamab Vedotin (RC48) - MIBC | Phase 3 | Recruiting | Zhiquan Hu | 170 | 2026-07-01 | 2026-07-09 |
| Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer Radiochemotherapy, Radical cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Brazilian Clinical Research Institute | 336 | 2026-06-01 | 2026-02-12 |
| Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma Radical cystectomy - Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma | Phase 2 | Recruiting | Yale University | 32 | 2025-11-26 | 2026-10-07 |
| Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy Neoadjuvant Chemotherapy, Radical Cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Recruiting | Assiut University | 76 | 2025-09-01 | 2025-10-02 |
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy Reproductive organ sparing radical cystectomy, Radical cystectomy - Urothelial Carcinoma Bladder | Phase 2 | Recruiting | University of Florida | 127 | 2024-08-30 | 2026-09-09 |
| RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients DisitamabVedotinForIicction Toripalimab - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 55 | 2024-06-19 | 2026-10-08 |
| Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma Adebrelimab, Etoposide, Cisplatin - Neuroendocrine Carcinoma of the Bladder, Bladder Cancer | Phase 2 | Recruiting | RenJi Hospital | 22 | 2023-11-16 | 2025-12-08 |
| Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan - Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Terminated | University of Washington | 4 | 2023-06-15 | 2026-04-27 |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 712 | 2021-08-05 | 2026-06-04 |
| Robotic Radical Cystectomy Outcomes Radical Cystectomy - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Recruiting | University of Florence | 500 | 2021-04-29 | 2021-05-25 | |
| Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer Cisplatin, Doxorubicin, Methotrexate - Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | Phase 2 | Completed | University of Washington | 17 | 2020-11-24 | 2025-09-18 |
| Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer Radical Cystectomy - Urinary Bladder Neoplasms | Not applicable | Completed | Copenhagen University Hospital, Rigshospitalet | 50 | 2019-06-06 | 2021-01-26 |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim - Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 237 | 2018-12-10 | 2026-10-16 |
| A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy Nivolumab, Ipilimumab, Radical cystectomy - Bladder Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2018-04-25 | 2026-02-17 |
| Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors Biopsy, High-Intensity Focused Ultrasound Ablation, Laboratory Biomarker Analysis - Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma | Not applicable | Withdrawn | University of Southern California | 2018-01-22 | 2018-01-02 |
Showing 20 of 36. Sign in to see all of them.
Urinary Bladder Neoplasms (24) · Carcinoma, Transitional Cell (4) · Carcinoma, Renal Cell (1) · Cone Dystrophy 3 (1) · Disease Progression (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1)
University of Washington (4) · Memorial Sloan Kettering Cancer Center (3) · University of Southern California (3) · Radiation Therapy Oncology Group (2) · Alliance for Clinical Trials in Oncology (1) · Assiut University (1) · AstraZeneca (1) · Brazilian Clinical Research Institute (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dana-Farber Cancer Institute (1) · Eli Lilly and Company (1) · Fox Chase Cancer Center (1) · Hoosier Cancer Research Network (1) · IRCCS San Raffaele (1) · Ligartis GmbH (1)
United States (24) · Italy (4) · China (3) · Brazil (2) · Canada (2) · Germany (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Chile (1) · Denmark (1) · Egypt (1) · France (1) · Greece (1)
Noah Hahn, M.D. (2) · Petros Grivas (2) · Abai Xu, doctor (1) · Alexander Kutikov, MD (1) · Amr Darwish, Lecturer (1) · Anthony L. Zietman, MD (1) · Arcangelo Sebastianelli, MD (1) · Brian Costello (1) · Charlene Mantia, MD (1) · Cheryl T. Lee, MD (1) · Chin-Lee Wu, MD, PhD (1) · Daniel Gorovets, MD (1) · David C Smith, MD (1) · David I Quinn, MD (1)
PMID 20089114, PMID 21205754, PMID 23228446, PMID 23706253, PMID 23823157, PMID 25366678, PMID 33109737, PMID 33430820, PMID 36639814, PMID 38865671, PMID 40329651, PMID 41193372
P30CA014089 (3), 2016 (1), P30CA015083 (1), P30CA016086 (1), U10CA180821 (1), UL1TR001120 (1)